MARKET WIREReuters • 1h ago
US voters in a sour economic mood heading into midterm elections - ReutersUS voters in a sour economic mood heading into midterm elections Reuters
Why OKYO Stock dropped -2.00% Today — RQD Quant Desk Flash
$1.47 -2.00% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $1.46
OKYO Pharma Limited (OKYO) carries a Roarable Rating of D+ (Sell) with 52/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D+ • SELL / AVOID
Cap $78.7M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on OKYO Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is OKYO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, OKYO Pharma Limited (NASDAQ: OKYO) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 52/100 at a spot price of $1.47 (-2.00% 1D, market cap $78.7M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, OKYO ranks #273 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does OKYO compare to NMRA and ATRA in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), OKYO carries a Roarable D+ (52/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, NMRA (Neumora Therapeutics Inc.) holds a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $73.0M) and ATRA (Atara Biotherapeutics Inc.) posts a D+ grade (54/100 RQD, P/E N/A, ROIC 85.0%, cap $85.6M). Among the 5-stock peer group, OKYO leads on earnings multiple (N/A) while ATRA leads on capital efficiency (85.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for OKYO?
▼
For OKYO Pharma Limited (OKYO), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #273 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $1.46 (-0.55%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.1% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 52/100 (D+) historically posted market-perform odds over rolling 90-day windows (-1.1% avg 90D alpha vs SPY • 50.1% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D+
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE-2.7% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for OKYO)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (52/100 Composite)
🔍 WHY OKYO SCORES 52/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (25% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (23% of score)
SEC XBRL Trailing 12 Months: 0.1% FCF Margin ($2.2M FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Whale & Options Positioning8/20 pts (-12 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-12 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$1.42-0.7% Next Q
44
Q2 (-2Q)Grade D$1.41-0.7% Next Q
47
Q3 (-1Q)Grade D$1.40+5% Next Q
49
CurrentGrade D+$1.47-1.1% Hist 90D α
52
Trajectory: D (44) → D+ (52)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a OKYO Turnaround Squeeze
While OKYO currently carries a cautious 52/100 (D+) rating due to Whale & Options Positioning (8/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.44) and Max Pain ($1.54) forces dealer call-delta covering toward $3.36.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $OKYO• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “OKYO Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why OKYO Stock dropped -2.00% Today — RQD Quant Desk Flash
OKYO Pharma Limited (OKYO) dropped -2.00% to $1.47, trading at 11% of its 52-week range ($1.26 – $3.2). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 11% of its 52-week range ($1.26 – $3.2) with RSI-14 at 52.8 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $1.47 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D+ (Sell) backed by 52% gross margin and $2.2M annual free cash flow.
Live OKYO Headlines & Catalysts
MARKET WIREReuters • 2h ago
China's foreign minister pushes for dialogue to resolve Middle East conflict - ReutersChina's foreign minister pushes for dialogue to resolve Middle East conflict Reuters
MARKET WIREReuters • 2h ago
COMMENTARY: Asia's crude oil imports back to pre-war levels but refined fuels lag - ReutersCOMMENTARY: Asia's crude oil imports back to pre-war levels but refined fuels lag Reuters
MARKET WIREReuters • 2h ago
Iranians have left Doha talks, draft proposal for US deal being circulated, official says - ReutersIranians have left Doha talks, draft proposal for US deal being circulated, official says Reuters
MARKET WIREReuters • 6h ago
Saudi civil defence sounds all-clear after alerts in southern cities - ReutersSaudi civil defence sounds all-clear after alerts in southern cities Reuters
MARKET WIREReuters • 6h ago
World's energy supply buffers have been eroded, ADNOC CEO says - ReutersWorld's energy supply buffers have been eroded, ADNOC CEO says Reuters
MARKET WIREReuters • 6h ago
Afghanistan asks US to act responsibly on deporting Afghan immigrants back home - ReutersAfghanistan asks US to act responsibly on deporting Afghan immigrants back home Reuters
MARKET WIREReuters • 7h ago
Anthropic plans to sell $3.5 billion of shares to Japan investors in IPO, filing shows - ReutersAnthropic plans to sell $3.5 billion of shares to Japan investors in IPO, filing shows Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring OKYO)
- ✓Walkthrough of OKYO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
OKYO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -5.77%▼ DESCENDING CHANNEL
2026-10-30O $1.46H $1.49L $1.40C $1.47VOL 107.5K
RES: $1.64SUP: $1.23SMA50: $1.44SMA200: $1.62
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
OKYO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on OKYO today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for OKYO. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for OKYO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (OKYO)
Health Care Rank #273 of 1016
⚔️ NMRA vs OKYO Full Matrix →
1. Head-to-Head Health Care Peer Comparison (OKYO vs. NMRA, ATRA, CRDF, GRML)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, OKYO Pharma Limited (OKYO) ranks #273 by composite RQD confidence (52/100, grade D+) and #693 by equity capitalization ($78.7M). Within this direct 5-issuer industry benchmark cohort, OKYO leads on earnings valuation at N/A trailing P/E, while ATRA leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. ATRA currently holds the highest overall quantitative score in the immediate peer group at 54/100 (D+) compared with OKYO at 52/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| OKYO
ACTIVE
OKYO Pharma Limited | D+ | 52/100 | — | — | — | -2.00% | $78.7M | Benchmark Subject |
| NMRA Neumora Therapeutics Inc. | D- | 42/100 | — | — | -35.0% | -5.43% | $73.0M | /nmra-vs-okyo → |
| ATRA Atara Biotherapeutics Inc. | D+ | 54/100 | — | — | 85.0% | -6.10% | $85.6M | /atra-vs-okyo → |
| CRDF Cardiff Oncology Inc. | D- | 41/100 | — | — | -35.0% | -2.46% | $70.9M | /crdf-vs-okyo → |
| GRML Greenland Mines Ltd. | E | 32/100 | — | — | -35.0% | -10.89% | $70.3M | /grml-vs-okyo → |
2. OKYO Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics
TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOTOKYO Pharma Limited (OKYO) operates in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care) with an equity capitalization of $78.7M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
3. OKYO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs OKYO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, OKYO Pharma Limited (NASDAQ: OKYO) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 52/100 at a spot price of $1.47 (-2.00% 1D, market cap $78.7M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, OKYO ranks #273 in composite RQD confidence.
How does OKYO compare to NMRA and ATRA in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), OKYO carries a Roarable D+ (52/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, NMRA (Neumora Therapeutics Inc.) holds a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $73.0M) and ATRA (Atara Biotherapeutics Inc.) posts a D+ grade (54/100 RQD, P/E N/A, ROIC 85.0%, cap $85.6M). Among the 5-stock peer group, OKYO leads on earnings multiple (N/A) while ATRA leads on capital efficiency (85.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for OKYO?
For OKYO Pharma Limited (OKYO), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #273 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is OKYO trading relative to its 50-day, 200-day, and 52-week technical levels?
OKYO last traded at $1.47 (-2.00% on volume of 107,544 shares), positioning the stock +2.08% above its 50-day simple moving average ($1.44) and -9.26% below its 200-day simple moving average ($1.62). Across its 52-week range of $1.26 to $3.20, OKYO sits at the 10.8% percentile with a 14-day RSI of 52.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.29 to $1.65).
OKYO Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is OKYO stock moving today?
Why OKYO Stock dropped -2.00% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.